High-dose cisplatin with sodium thiosulfate protection. 1985

C E Pfeifle, and S B Howell, and R D Felthouse, and T B Woliver, and P A Andrews, and M Markman, and M P Murphy

Nephrotoxicity frequently limits the dose of cisplatin to less than 120 mg/m2 per injection. Sodium thiosulfate is a neutralizing agent for cisplatin that protects against renal damage. To determine whether injection of thiosulfate would permit larger doses of cisplatin to be administered, a fixed 9.9-g/m2 dose of thiosulfate was given intravenously over three hours concurrently with escalating doses of cisplatin. Cisplatin was administered over the last two hours of the thiosulfate infusion. Using this technique, it was possible to escalate the cisplatin dose to 225 mg/m2 before dose-limiting toxicities were encountered. Comparison of cisplatin pharmacokinetics in patients treated with 202.5 mg/m2 plus thiosulfate to those in patients treated with 100 mg/m2 without thiosulfate indicated that there were no changes in the elimination rate constant, volume of distribution, or total body clearance of cisplatin. The total drug exposure for the plasma was approximately twofold at the higher cisplatin dose. This study demonstrates that concurrent administration of thiosulfate permits at least a twofold increase in dose and total exposure to cisplatin.

UI MeSH Term Description Entries
D007263 Infusions, Parenteral The administration of liquid medication, nutrient, or other fluid through some other route than the alimentary canal, usually over minutes or hours, either by gravity flow or often by infusion pumping. Intra-Abdominal Infusions,Intraperitoneal Infusions,Parenteral Infusions,Peritoneal Infusions,Infusion, Intra-Abdominal,Infusion, Intraperitoneal,Infusion, Parenteral,Infusion, Peritoneal,Infusions, Intra-Abdominal,Infusions, Intraperitoneal,Infusions, Peritoneal,Intra Abdominal Infusions,Intra-Abdominal Infusion,Intraperitoneal Infusion,Parenteral Infusion,Peritoneal Infusion
D007674 Kidney Diseases Pathological processes of the KIDNEY or its component tissues. Disease, Kidney,Diseases, Kidney,Kidney Disease
D007700 Kinetics The rate dynamics in chemical or physical systems.
D008274 Magnesium A metallic element that has the atomic symbol Mg, atomic number 12, and atomic weight 24.31. It is important for the activity of many enzymes, especially those involved in OXIDATIVE PHOSPHORYLATION.
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D009325 Nausea An unpleasant sensation in the stomach usually accompanied by the urge to vomit. Common causes are early pregnancy, sea and motion sickness, emotional stress, intense pain, food poisoning, and various enteroviruses.
D009369 Neoplasms New abnormal growth of tissue. Malignant neoplasms show a greater degree of anaplasia and have the properties of invasion and metastasis, compared to benign neoplasms. Benign Neoplasm,Cancer,Malignant Neoplasm,Tumor,Tumors,Benign Neoplasms,Malignancy,Malignant Neoplasms,Neoplasia,Neoplasm,Neoplasms, Benign,Cancers,Malignancies,Neoplasias,Neoplasm, Benign,Neoplasm, Malignant,Neoplasms, Malignant
D002945 Cisplatin An inorganic and water-soluble platinum complex. After undergoing hydrolysis, it reacts with DNA to produce both intra and interstrand crosslinks. These crosslinks appear to impair replication and transcription of DNA. The cytotoxicity of cisplatin correlates with cellular arrest in the G2 phase of the cell cycle. Platinum Diamminodichloride,cis-Diamminedichloroplatinum(II),cis-Dichlorodiammineplatinum(II),Biocisplatinum,Dichlorodiammineplatinum,NSC-119875,Platidiam,Platino,Platinol,cis-Diamminedichloroplatinum,cis-Platinum,Diamminodichloride, Platinum,cis Diamminedichloroplatinum,cis Platinum
D004347 Drug Interactions The action of a drug that may affect the activity, metabolism, or toxicity of another drug. Drug Interaction,Interaction, Drug,Interactions, Drug

Related Publications

C E Pfeifle, and S B Howell, and R D Felthouse, and T B Woliver, and P A Andrews, and M Markman, and M P Murphy
September 1985, European journal of cancer & clinical oncology,
C E Pfeifle, and S B Howell, and R D Felthouse, and T B Woliver, and P A Andrews, and M Markman, and M P Murphy
December 1985, Gan to kagaku ryoho. Cancer & chemotherapy,
C E Pfeifle, and S B Howell, and R D Felthouse, and T B Woliver, and P A Andrews, and M Markman, and M P Murphy
October 1986, American journal of clinical oncology,
C E Pfeifle, and S B Howell, and R D Felthouse, and T B Woliver, and P A Andrews, and M Markman, and M P Murphy
January 1991, Journal of cancer research and clinical oncology,
C E Pfeifle, and S B Howell, and R D Felthouse, and T B Woliver, and P A Andrews, and M Markman, and M P Murphy
April 1993, Journal of surgical oncology,
C E Pfeifle, and S B Howell, and R D Felthouse, and T B Woliver, and P A Andrews, and M Markman, and M P Murphy
June 2018, The New England journal of medicine,
C E Pfeifle, and S B Howell, and R D Felthouse, and T B Woliver, and P A Andrews, and M Markman, and M P Murphy
April 1985, Gan to kagaku ryoho. Cancer & chemotherapy,
C E Pfeifle, and S B Howell, and R D Felthouse, and T B Woliver, and P A Andrews, and M Markman, and M P Murphy
May 1993, Gynecologic oncology,
C E Pfeifle, and S B Howell, and R D Felthouse, and T B Woliver, and P A Andrews, and M Markman, and M P Murphy
January 1987, Journal of clinical pharmacology,
C E Pfeifle, and S B Howell, and R D Felthouse, and T B Woliver, and P A Andrews, and M Markman, and M P Murphy
February 1980, American journal of hospital pharmacy,
Copied contents to your clipboard!